Comparative Pharmacology
Head-to-head clinical analysis: DERMOTIC versus MICORT HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMOTIC versus MICORT HC.
DERMOTIC vs MICORT-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dermotic (fluocinolone acetonide) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins inhibit the release of arachidonic acid, thereby suppressing the synthesis of prostaglandins and leukotrienes, leading to anti-inflammatory and immunosuppressive effects.
Topical corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release, thereby exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Each 1 mL contains 1 mg betamethasone valerate, 10 mg neomycin sulfate, 10,000 units polymyxin B sulfate. Apply 3-4 drops into affected ear(s) 2-3 times daily for 7-10 days.
Topical: Apply a thin film to affected area 2-4 times daily. Rectal: Insert one suppository (25 mg) rectally twice daily (morning and evening) for 2-3 weeks, then taper as needed.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours. In patients with renal impairment, half-life may be prolonged; dose adjustment recommended for CrCl <30 mL/min.
Terminal elimination half-life is 1.5-2.5 hours; clinical duration of action is longer due to genomic effects lasting 8-12 hours.
Primarily renal excretion of unchanged drug (approximately 70-80%) with the remainder metabolized and excreted via biliary/fecal routes (20-30%).
Renal (approximately 70% as inactive metabolites, <5% unchanged); fecal (approximately 30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid